S-1/A: Inspire Veterinary Faces Nasdaq Delisting Amidst Mixed Financials

Inspire Veterinary Partners reports reduced net losses and improved cash flow from operations, but faces imminent Nasdaq delisting and ongoing 'going concern' doubts.

Summary

• Inspire Veterinary Partners, Inc. (IVP) received a Nasdaq delisting notice on November 13, 2025, due to non-compliance with the minimum bid price requirement, with a hearing scheduled for January 13, 2026.
• The company is not eligible for a standard compliance period due to multiple reverse stock splits over the past two years.
• Net loss for the nine months ended September 30, 2025, improved by 23% to $(7,975,878) from $(10,297,539) in the prior year period.
• Cash used in operating activities significantly improved, decreasing to $(3,555,276) for the nine months ended September 30, 2025, from $(9,328,339) in the same period of 2024.
• Total revenue for the nine months ended September 30, 2025, decreased by 8% to $12,238,875, primarily due to the divestiture of Kauai Veterinary Clinic (KVC) in September 2024.
• Interest expense for the nine months ended September 30, 2025, decreased by 50.5% to $(1,385,891) from $(2,801,491) in the prior year.
• The company completed a private placement of Series B convertible preferred stock and warrants, raising approximately $5 million on July 29, 2025, and an additional $1 million on September 9, 2025.
• New Senior Convertible Promissory Notes were issued on November 5, 2025, with a principal amount of $178,571.43 each (30% original issue discount) and a 10% annual interest rate, maturing August 5, 2026.
• Promissory notes totaling $1,250,000 in principal ($1,000,000 purchase price) were issued to Target Capital LLC on June 10 and June 30, 2025, for general working capital.
• The company acquired DeBary Animal Clinic on June 4, 2025, for approximately $1,942,500 in cash and restricted Class A common stock.
• An agreement was made on December 1, 2025, to redeem 2,027 shares of Series B Preferred Stock for approximately $2.7 million, and the Floor Price for Series B conversion was lowered to $0.05.
• The company continues to operate with an accumulated deficit of $(44,326,159) and negative working capital of $(5,894,301) as of September 30, 2025, raising substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 4

Explanation: While the company shows significant improvements in net loss and operational cash flow, the imminent Nasdaq delisting and ongoing 'going concern' doubts present substantial negative sentiment. Recent capital raises provide some liquidity but are often at high effective interest rates, reflecting underlying financial stress.

Positives

• Net loss decreased by 23% for the nine months ended September 30, 2025, to $(7,975,878) from $(10,297,539) in the prior year, indicating improved loss management.
• Cash used in operating activities significantly improved, decreasing by $5,773,063 to $(3,555,276) for the nine months ended September 30, 2025, compared to $(9,328,339) in the same period of 2024.
• Interest expense decreased by 50.5% for the nine months ended September 30, 2025, to $(1,385,891), reflecting better debt management or lower high-interest financing.
• General and administrative expenses decreased by 7% for the nine months ended September 30, 2025, to $7,514,420, indicating cost control efforts.
• The company successfully raised $6 million through a private placement of Series B preferred stock and warrants in July and September 2025.
• The acquisition of DeBary Animal Clinic on June 4, 2025, for $1,942,500 expands the company's network to 14 veterinary hospitals in nine states.
• The company secured additional financing through Senior Convertible Promissory Notes ($250,000 purchase price) and Promissory Notes to Target Capital LLC ($1,000,000 purchase price) in late 2025.
• Stockholder approval was obtained on September 10, 2025, for the issuance of conversion shares at a conversion price below the conversion price, providing flexibility for future conversions.

Negatives

• The company received a Nasdaq delisting notice on November 13, 2025, due to non-compliance with the minimum bid price requirement, and is not eligible for a standard compliance period.
• There is substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative working capital of $(5,894,301) as of September 30, 2025.
• Total revenue for the nine months ended September 30, 2025, decreased by 8% to $12,238,875, primarily due to the divestiture of Kauai Veterinary Clinic.
• The company's accumulated deficit increased to $(44,326,159) as of September 30, 2025, from $(36,350,281) as of December 31, 2024.
• Cash and cash equivalents decreased to $341,746 as of September 30, 2025, from $523,690 as of December 31, 2024.
• The company continues to rely on high-interest financing arrangements, such as merchant cash advances with effective interest rates up to 52%.
• The trading price of the company's Common Stock was $0.12 per share on November 28, 2025, significantly below the $1.00 Nasdaq minimum bid price.
• The company's management has limited experience as senior management of a public company, which could impact compliance and operations.

Risks

• Limited operating history and unprofitability, with an accumulated deficit of $44,326,159 as of September 30, 2025, and no assurance of future profitability.
• Inability to attract and retain senior management, which could hinder successful integration of acquisitions and scaling of services.
• Need to raise additional capital to fund operations and acquisitions, with no assurance of availability on acceptable terms, potentially leading to dilution or restrictive debt covenants.
• Significant increased expenses and administrative burdens as a public company, diverting management's attention and potentially impacting financial results.
• Risks associated with growth through acquisitions, including integration problems, unanticipated costs, potential loss of key employees, and unknown liabilities.
• Potential dilution of ownership from future equity financings or conversions of debt instruments.
• Limitations on the ability to use net operating loss carryforwards due to potential future ownership changes under Code Section 382.
• Failure to maintain effective internal controls over financial reporting, which could lead to adverse regulatory consequences and harm investor confidence.
• Successor liabilities from acquired businesses due to conduct prior to acquisition, including tax, regulatory, employee, or contract matters.
• Additional complexity and cost associated with purchasing real estate with hospital acquisitions, including building inspections, zoning, and permitting variabilities.
• Inaccurate estimates of the addressable market size, potentially leading to lower-than-anticipated future growth.
• Inability to successfully execute growth strategies or manage and sustain growth, impacting brand, business, and operating results.
• Difficulties recruiting and retaining skilled veterinarians and technical staff due to shortages, potentially increasing labor costs and disrupting business.
• Negative publicity from claims of improper animal care, which could harm public perception, sales, and profitability.
• Fluctuations in quarterly operating results due to timing of expenses, acquisitions, closures, and other factors.
• Harm to business if computer network security or databases containing sensitive information are compromised, leading to liability, litigation, and reputational damage.
• Highly competitive animal health industry with larger competitors having greater financial, marketing, and technical resources.
• Inability to adequately protect intellectual property rights, leading to significant financial and managerial resource expenditure.
• Exposure to litigation, which can be expensive, time-consuming, and divert management attention.
• Impact of natural disasters and other events beyond control on operations, supply chains, and financial condition.
• Various government regulations limiting or delaying the ability to develop and commercialize services, or leading to fines and litigation.
• Failure to comply with state or federal regulations covering dispensing of prescription pet medications, including controlled substances.
• Costs associated with environmental, health, and safety laws and regulations.
• Potential delisting of Class A common stock from Nasdaq, leading to limited market quotations, reduced liquidity, and potential 'penny stock' designation.
• Volatility in the trading price of Common Stock, leading to substantial losses for investors.
• Lack of intent to pay cash dividends for the foreseeable future, making investment return dependent on stock price appreciation.
• Subordination of shares to all debts and liabilities, increasing the risk of losing the entire investment in liquidation.
• Ability of the board of directors to designate and issue new classes of stock (including Class B common stock) that could be superior to or adversely affect Class A common stock holders.
• Control of approximately 54.5% of voting power by non-independent directors, officers, and their affiliates, potentially influencing corporate actions against other investors' interests.

Future Outlook

The company plans to continue its growth strategy through acquisitions, targeting five to ten new veterinary hospitals per year across the United States. This expansion will include mixed animal and specialty care facilities, moving beyond small companion animal hospitals. Management intends to seek multi-unit practices with regional presence to accelerate growth and provide internal benefits like case referrals and career pathing. The company also aims to expand its service offerings to include tele-veterinarian services, which will require significant investments in information technology and training.

Management Comments

• Management believes the breakdown of gross revenue into service and product categories provides meaningful measures to protect the service channel and derive the majority of revenue from services and expertise not susceptible to disruption from other channels.
• Management believes the ratio metric of service-to-product revenue is useful for ensuring caseload is revenue positive and avoiding clinician time underutilization.
• Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern.

Industry Context

The pet care industry is highly fragmented, with over a dozen national and approximately 25 regional consolidators owning around 7,500 of the nearly 30,000 veterinary hospitals in the U.S. Larger competitors like Mars and NVA collectively own about 4,000 hospitals. Inspire Veterinary Partners aims to differentiate itself through a broad employee equity offering, a personalized acquisition and integration approach that allows acquired practices to maintain their identity, a coaching and development-based workflow customized for clinicians, and a conservative valuation process based on a 3-year look back for long-term ROI.

Comparison to Industry Standards

• The company aims to match the industry target metric of 70% to 80% of gross revenue derived from services (examination fees, diagnostics, surgery), which is considered less susceptible to disruption from non-veterinary channels. For the nine months ended September 30, 2025, service revenue was 74% of total revenue, aligning with this target.
• The company uses Revenue Per Patient Per day (RPP) and Average Patient Charge (APC) metrics, sometimes referred to as 'quality medicine metrics' in the veterinary service industry, to analyze the comprehensive nature of diagnostics and services provided by each hospital. This aligns with industry best practices for optimizing clinician time and labor profitability.
• The company's valuation process for acquisitions is based on a 3-year look back and conservative enterprise values, designed to support long-term Return On Investment, which contrasts with competitors who may rely on trailing twelve measures or buy at inflated multiples of EBITDA or revenue.

Management Changes

Corporate Governance

Legal Proceedings

• The company is addressing a lawsuit in Ohio State Court against a former animal clinic and hospital owner for violating a non-compete agreement post-employment. The company anticipates a favorable judgment and compensation below a certain threshold.

Related Party Transactions

• Sale of Kauai Veterinary Clinic (KVC) on September 20, 2024, to Kauai RE Holdings LLC, where Charles Keiser, DVM (father of board member Charles Stith Keiser) is a member.
• Consulting services from Blue Heron Consulting (BHC), where Charles Stith Keiser (director) is COO and his father is Chief Visionary Officer. The company incurred $94,043 in expenses for the nine months ended September 30, 2025, and $83,168 for the nine months ended September 30, 2024.
• Kimball Carr (CEO) received a warrant to purchase 20 Class A common shares on January 1, 2023, in consideration for his personal guaranty of company loans.
• FSB Commercial Loans and First Southern National Bank (FSB) loans are guaranteed by Kimball Carr (CEO) and Charles Stith Keiser (director).

Stakeholder Impact

• **Shareholders**: Face significant risk of delisting from Nasdaq, which could severely impact liquidity and stock value. Existing shareholders will experience dilution from recent and potential future capital raises. Class A common stockholders have significantly less voting power due to Class B common stock structure.
• **Employees**: The company's growth strategy through acquisitions and expansion of services (e.g., tele-veterinarian) could create new opportunities. However, staffing shortages for veterinarians and technicians pose a challenge. Employee stock option plans are offered as a differentiator.
• **Customers**: Expansion through acquisitions aims to provide comprehensive veterinary care, including preventive, surgical, and alternative procedures. Potential for new tele-veterinarian services could enhance access to care.
• **Creditors**: The company's recurring losses and 'going concern' doubt indicate elevated risk. Debt is secured by virtually all company assets, and some loans are personally guaranteed by the CEO and a director. High effective interest rates on short-term debt suggest higher cost of capital.
• **Management**: Faces significant challenges in addressing Nasdaq compliance, managing growth, and ensuring financial stability. Increased administrative burdens as a public company and the need to attract and retain senior management are critical.

Next Steps

• Attend Nasdaq Hearings Panel on January 13, 2026, to appeal delisting determination.
• Continue efforts to regain and maintain Nasdaq listing compliance.
• Seek additional funding through debt or equity financing to address going concern doubts and fund operations.
• Expand through acquisitions of existing veterinary hospitals (target 5-10 units per year), including mixed animal and specialty care facilities.
• Pursue multi-unit practices with regional presence to accelerate growth.
• Invest in information technology and training to implement tele-veterinarian services.

Key Dates

Recommendation

The company faces an imminent Nasdaq delisting, which would severely impair liquidity and likely lead to a substantial decline in share price. Despite some improvements in net loss and operational cash flow, the 'going concern' doubt, persistent accumulated deficit, and reliance on high-interest financing indicate significant financial instability. The stock price is already at $0.12, reflecting severe market distress. While capital raises provide temporary relief, the fundamental issues of profitability and market compliance remain critical and unresolved, making the stock a high-risk, speculative investment with substantial downside potential.

Keywords

Veterinary Services, Animal Health, SEC Filing, Nasdaq Delisting, Going Concern, Acquisitions, Convertible Notes, Preferred Stock, Warrants, Financial Performance, Risk Factors, Corporate Governance, Capital Raise, Stock Split, Pet Care Industry